Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Advanced Medical Solutions Group's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Advanced Medical Solutions Group was 30.38. The lowest was 13.10. And the median was 19.29.
CHIX:AMSl's Price-to-Net-Cash is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 9.73 * Ranked among companies with meaningful Price-to-Net-Cash only.
Advanced Medical Solutions Group (CHIX:AMSl) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Advanced Medical Solutions Group Net Cash per Share Related Terms
Advanced Medical Solutions Group Net Cash per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group Net Cash per Share Chart
CHIX:AMSL vs ISRG, BDX, MDLN: Net Cash per Share Comparison
For the Medical Instruments & Supplies subindustry, Advanced Medical Solutions Group's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Advanced Medical Solutions Group Price-to-Net-Cash vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Advanced Medical Solutions Group's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Advanced Medical Solutions Group's Price-to-Net-Cash falls into.
Advanced Medical Solutions Group Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Advanced Medical Solutions Group (CHIX:AMSL) has a Net Cash per Share of £-0.55 as of Dec. 2025. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Advanced Medical Solutions Group and its competitors. Over the past decade, Advanced Medical Solutions Group's Net Cash per Share has ranged from 13.10 to 30.38. According to the industry distribution chart, Advanced Medical Solutions Group ranks #999999 out of 301 companies in the Medical Devices & Instruments industry.
Is Advanced Medical Solutions Group's Net Cash per Share too high?
Advanced Medical Solutions Group's current Net Cash per Share is £-0.55. Over the past 10 years, this metric has ranged from a low of 13.10 to a high of 30.38. Based on the distribution chart, Advanced Medical Solutions Group ranks #999999 out of 301 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Advanced Medical Solutions Group has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Advanced Medical Solutions Group's Net Cash per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Advanced Medical Solutions Group ranks #999999 out of 301 companies for Net Cash per Share. This places Advanced Medical Solutions Group in the lower half of its industry. The industry median Net Cash per Share is 9.73. Historically, Advanced Medical Solutions Group's own Net Cash per Share has ranged from 13.10 to 30.38 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Medical Devices & Instruments company?
The median Net Cash per Share among Medical Devices & Instruments companies is 9.73, based on 301 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Advanced Medical Solutions Group and its competitors. For the Medical Devices & Instruments industry, the median Net Cash per Share is 9.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Advanced Medical Solutions Group's current Net Cash per Share is £-0.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced Medical Solutions Group stock overvalued right now?
Based on GuruFocus' analysis, Advanced Medical Solutions Group (CHIX:AMSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £3.74, compared to a current price of £2.81 — trading 24.9% below its estimated fair value. The current Net Cash per Share is £-0.55. Advanced Medical Solutions Group's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Advanced Medical Solutions Group (CHIX:AMSL), the current Net Cash per Share is £-0.55 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Advanced Medical Solutions Group (CHIX:AMSL) Overvalued in 2026?
Based on GuruFocus' analysis, Advanced Medical Solutions Group stock appears to be undervalued.
The current stock price of £2.81 is trading 24.9% below its estimated GF Value™ of £3.74.
GuruFocus considers Advanced Medical Solutions Group to be Modestly Undervalued.
Key valuation signals for CHIX:AMSL:
Net Cash per Share: £-0.55
GF Value™: £3.74 vs. price of £2.81 (24.9% below fair value)
No single metric tells the full story. See the CHIX:AMSL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Advanced Medical Solutions Group PLC is engaged in developing and manufacturing wound-care products for other healthcare manufacturers. AMS' key branded products include the ActivHeal franchise of hydrogel, hydrocolloid, foam, and alginate wound dressings. The firm also manufactures and markets a suite of branded products in surgical use, including the LiquiBand franchise for tissue adhesion and the Resorba line of sutures and collagen-based products for tissue repair. The company's segment includes: Surgical and Woundcare, of which the Surgical segment derives maximum revenue. Geographically, the company operates in the United Kingdom, Germany, France, the rest of Europe, the United States of America, and the rest of the world.
79GF Score
Get the complete analysis for CHIX:AMSL
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMSL has been successfully added to your 
